My research interest focuses on developmental therapeutics for sarcomas, with a primary emphasis on gastrointestinal stromal tumors (GIST). Management of GIST has been transformed by the use of tyrosine kinase inhibitors (TKIs). I have lead investigator-initiated and industry sponsored studies in the testing of multiple TKIs alone or with novel agents. I was a leading investigator in trials of imatinib in the metastatic, adjuvant and neoadjuvant settings. I have served on the scientific investigator steering committees for the trials developing regorafenib, repretinib and avapritinib. I have participated in the NIH Wild type GIST clinic, which has served as a key resource for the understanding of the biology and treatment of this subtype of GIST, many of which are now understood to have deficiencies in the function of succinate dehydrogenase family of enzymes. I have been involved with translational studies exploring the biology of GIST utilizing in vitro and in vivo models, leading to human clinical trials.